TB and HIV in the Russian Federation: Risk Factors of MDR-TB in HIV-infected Patients (review)

MedAlliance ◽  
2020 ◽  
pp. 6-13

In the article, a review of foreign and Russian literature suggests that both multidrug-resistant tuberculosis spread and the HIV epidemic are factors maintaining the high tuberculosis burden worldwide and in the Russian Federation. The main transmission pathway for HIV-infection in the Russian Federation, as well as in other countries of Eastern Europe and Central Asia, is now attributed to heterosexual contact, which has surpassed the intravenous injection route of transmission. A rise in heterosexual risk of HIV transmission is accelerating epidemic progression amongst the general population, thereby contributing to a generalization of the epidemic process. The authors also provide an analytical review of publications related to risk factors for multidrug-resistant tuberculosis development in HIV-infected patients. It is found that such literature is limited in foreign countries, as well as in the Russian Federation. There is information about the general role of HIV infection in tuberculosis burden, but the influence of socio-demographic, epidemiological and clinical factors for multidrug-resistant tuberculosis development in people living with HIV is not sufficiently studied. Thus, there is a need for further studies designed to analyze the socio-demographic, epidemiological and clinical characteristics of patients with multidrug-resistant tuberculosis and HIV co-infection in comparison with those who are HIV-negative. Knowledge of the main risk factors for multidrug-resistant tuberculosis development in people living with HIV will allow selective and targeted use of resources to achieve effective outcomes in treatment of HIV/TB co-infected patients.

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Zeeba Zahra Sultana ◽  
Farhana Ul Hoque ◽  
Joseph Beyene ◽  
Md. Akhlak-Ul-Islam ◽  
Md Hasinur Rahman Khan ◽  
...  

An amendment to this paper has been published and can be accessed via the original article.


PLoS ONE ◽  
2015 ◽  
Vol 10 (10) ◽  
pp. e0139986 ◽  
Author(s):  
Charoen Chuchottaworn ◽  
Vipa Thanachartwet ◽  
Piamlarp Sangsayunh ◽  
Thu Zar Myint Than ◽  
Duangjai Sahassananda ◽  
...  

2020 ◽  
Author(s):  
Nomawethu Somfongo ◽  
Wiseman Mupindu ◽  
nozuko mangi

Abstract Background Multi Drug Resistance (MDR) Tuberculosis (TB) is a global risk. Several suboptimal results were noticed which resulted to introduction of a standardised short regimen of 9-12 to optimise favourable outcomes. This new intervention has not been evaluated for effectiveness since inception in the Eastern Cape Province. Objective: T o evaluate multidrug resistant tuberculosis conversion rate following initiation on short regimen. Methods A retrospective study using a descriptive design was used to collect data from conveniently sampled 71 documents at Nkqubela TB and Duncan Village Day hospitals. Data were collected using a self-designed structured questionnaire and analysed using Statistical Packages for Social Sciences (SPSS) version 24. Results Sixteen percent (n=19) of 71 records had no consecutive smear results. Demographic findings showed that the majority of the affected age group was between the ages of 36-45 years in both genders (34.7%, n=47) with males being highly affected more than females. The majority of participants were unemployed (51.7%), people living with HIV/AIDS (62.7%), use alcohol and smoking. Conversion rate was 68, 5%. Conclusion There is a need to review EDR web to accommodate sputum results irrespective of TB treatment start date. An extensive, ongoing counselling, support and health education needs to be provided for patients and families until the completion of treatment to emphasize the importance of monthly sputum collection and importance of treatment adherence. Clinicians need to strengthen their counselling and education skills. The introduction of short regimen to treat MDR has shown an improved sputum conversion rate in RR/MDR TB.


Sign in / Sign up

Export Citation Format

Share Document